Abstract
Eighty-seven women with advanced cervical carcinoma were treated, in 10 years, with systemic antiblastic chemotherapy using 4 different regimens in 4 successive periods: first VBM, then MAB, CDDP and finally BMFt. Selection of a regimen different than the initial one aimed to obtain a better response and less toxicity. As a whole, 25% positive responses (CR and PR) and an SD which varied from 31.4% to 58.3% were obtained. Among the regimens used, the one with bleomycin, methotrexate and ftorafur had a response rate (OR + SD) of 75% which is higher than what was obtained with regimens VBM and MAB and is similar to CDDP. Less toxicity with greater compliance were shown.
MeSH terms
-
Adult
-
Aged
-
Aged, 80 and over
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Bleomycin / administration & dosage
-
Bleomycin / adverse effects
-
Cisplatin / adverse effects
-
Cisplatin / therapeutic use
-
Doxorubicin / administration & dosage
-
Doxorubicin / adverse effects
-
Female
-
Humans
-
Methotrexate / administration & dosage
-
Methotrexate / adverse effects
-
Middle Aged
-
Neoplasm Recurrence, Local / drug therapy*
-
Tegafur / administration & dosage
-
Tegafur / adverse effects
-
Uterine Cervical Neoplasms / drug therapy*
-
Vincristine / administration & dosage
-
Vincristine / adverse effects
Substances
-
Bleomycin
-
Tegafur
-
Vincristine
-
Doxorubicin
-
Cisplatin
-
Methotrexate
Supplementary concepts
-
BMFt protocol
-
MAB protocol
-
VBM protocol